2021
Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020
Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Network Open 2021, 4: e2131744. PMID: 34705010, PMCID: PMC8552059, DOI: 10.1001/jamanetworkopen.2021.31744.Peer-Reviewed Original ResearchConceptsNeuroendocrine neoplasmsClinical trialsNational Cancer Institute Clinical TrialsEU Clinical Trials RegisterCoprimary end pointsObjective response rateProgression-free survivalClinical Trials RegisterKi-67 indexAllied Health LiteratureQuality improvement studyPhase IISpecific disease populationsWeb of ScienceDrug licensureTrials RegisterCochrane DatabaseTumor differentiationNovel agentsDisease populationInclusion criteriaMAIN OUTCOMECumulative IndexEnrollment periodResponse rate
2013
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors
Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas 2013, 42: 557-577. PMID: 23591432, PMCID: PMC4304762, DOI: 10.1097/mpa.0b013e31828e34a4.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsConsensus guidelinesNorth American Neuroendocrine Tumor SocietyPhase 3 trialTreatment of patientsHeterogeneous clinical presentationPractice-changing outcomesClinical presentationNovel agentsAnatomic locationTumorsHeterogeneous groupDegree of aggressivenessTreatmentDiseaseConsensus tableGuidelinesRigorous evaluationEverolimusSunitinibPatientsMalignancyPhysiciansTrials